<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To examine IgG anti-beta 2 glycoprotein I (anti-beta 2 GPI) binding in 82 sera referred for anticardiolipin antibody (aCL) testing and to develop preliminary clinical correlations with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Immunoassay of IgG cofactor dependent aCL and IgG anti-beta 2 GPI antibodies and retrospective chart review </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Forty-four sera exhibited <z:mpath ids='MPATH_458'>normal</z:mpath> (&lt; or = 22 GPL units) aCL activity, 18 had moderate binding activity (23-45 GPL units), and 20 had high (&gt; or = 46 GPL units) binding activity to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Among these groups, 6 of the 20 sera in the high GPL group had elevated anti-beta 2 GPI </plain></SENT>
<SENT sid="4" pm="."><plain>This correlated strongly with 2 or more clinical manifestations of APS </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: Anti-beta 2 GPI activity may be a more valuable indicator of APS than aCL </plain></SENT>
</text></document>